Cambium Bio (ASX:CMB) Ending Cash Position: A$0.77 Mil (As of Dec. 2025)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.41
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Ending Cash Position?

Cambium Bio ASX:CMB 35 Ending Cash Position is A$0.77 Mil as of Dec. 2025. GuruFocus rates ASX:CMB with a GF Score™ of 35/100. The stock has 4 warning signs investors should review.

Cambium Bio's Ending Cash Position for the quarter that ended in Dec. 2025 was A$0.77 Mil.

Cambium Bio's quarterly Ending Cash Position declined from Dec. 2024 (A$0.55 Mil) to Jun. 2025 (A$0.17 Mil) but then increased from Jun. 2025 (A$0.17 Mil) to Dec. 2025 (A$0.77 Mil).

Cambium Bio's annual Ending Cash Position increased from Jun. 2023 (A$0.30 Mil) to Jun. 2024 (A$2.87 Mil) but then declined from Jun. 2024 (A$2.87 Mil) to Jun. 2025 (A$0.17 Mil).

Cambium Bio Ending Cash Position Related Terms

Cambium Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Cambium Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambium Bio Ending Cash Position Chart

Cambium Bio Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.79 0.10 0.30 2.87 0.17

Cambium Bio Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 2.87 0.55 0.17 0.77
ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cambium Bio's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.864+-2.698
=0.17

Cambium Bio's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.167+0.607
=0.77

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$0.77 Mil mean?
Cambium Bio (ASX:CMB) has a Ending Cash Position of A$0.77 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cambium Bio and its competitors.
Is Cambium Bio's Ending Cash Position too high?
Cambium Bio's current Ending Cash Position is A$0.77 Mil. Overall, Cambium Bio has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cambium Bio's Ending Cash Position compare to VRTX and REGN?
Cambium Bio's Ending Cash Position of A$0.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Cambium Bio and its competitors. Cambium Bio's current Ending Cash Position is A$0.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambium Bio stock overvalued right now?
Cambium Bio (ASX:CMB) has a current Ending Cash Position of A$0.77 Mil. The current Ending Cash Position is A$0.77 Mil. Cambium Bio's overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Cambium Bio (ASX:CMB), the current Ending Cash Position is A$0.77 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.41
Price